Acumen Pharmaceuticals (ABOS) Stock Highlights

2.37 | +2.6%

2024-11-23 05:34:35

Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what we believe to be a key underlying cause of Alzheimers disease. The companys lead drug candidate, ACU193, is a subclass monoclonal antibody which selectively targets amyloid-beta oligomers.

Statistics

Range Today

2.26 2.38

Volume Today 182.1K

Range 1 Year

2.08 5.09

Volume 1 Year 85.36M

Range 3 Year

1.81 11.31

Volume 3 Year 325.43M

Range 10 Year

1.81 26.98

Volume 10 Year 342.92M

Highlights

Market Capitalization 196.46M (small)

Floating Shares 32.42M

Current Price 2.37

Price To Earnings -2.87

Price To Book 0.81

Earnings Per Share -1.11

Payout Ratio 0%

Performance

Latest +2.6%

1 Month -11.9%

3 Months -17.42%

6 Months -37.96%

1 Year +0.42%

3 Years -76.16%

5 Years -90.88%

10 Years -90.88%

Benchmarks

Market Capitalization

216 / 368

Gross Profits

181 / 278

Total Revenue

0 / 300

Total Rank

282 / 368

Free Cashflow

173 / 352

Performance 5 years

281 / 368

Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.